At #EAU25, Dr. Yannic Volz (Ludwig-Maximilians-Universität München) introduced early insights from the ongoing PRACTICE trial (NCT06806059), a randomized, single-blinded study assessing the impact of structured physical activity before radical cystectomy…

At #EAU25, Dr. Vera R. and colleagues from Erasmus MC presented the first study to assess the environmental impact and staff requirements of radical cystectomy (RC) versus chemoradiation (CRT) for…

At #EAU25, Dr. Seth Lerner (Baylor College of Medicine) presented early findings from a Phase 1 study (NCT05483868) evaluating Bel-sar (AU-011)—a novel virus-like drug conjugate (VDC) for non-muscle invasive bladder…

Prostate biopsy remains the gold standard for diagnosing prostate cancer, but it carries risks such as infection, bleeding, and urinary obstruction. As a result, growing research interest has focused on developing “non-biopsy” diagnostic strategies. At the 2025 Annual Meeting of the European Association of Urology (EAU25), a study led by Professor Shouzhen Chen and Professor Benkang Shi from Qilu Hospital of Shandong University was selected for oral presentation. The study demonstrated that combining PSMA PET/CT, multiparametric MRI (PI-RADS score), and blood biomarkers—PHI and PSAD—can reduce the prostate cancer missed diagnosis rate to zero.